3D Medicines Inc. (1244.HK)

HKD 3.34

(-1.47%)

EBITDA Summary of 3D Medicines Inc.

  • 3D Medicines Inc.'s latest annual EBITDA in 2023 was -529.23 Million CNY , up 53.41% from previous year.
  • 3D Medicines Inc.'s latest quarterly EBITDA in 2024 Q2 was -63.55 Million CNY , down 0.0% from previous quarter.
  • 3D Medicines Inc. reported an annual EBITDA of -1.02 Billion CNY in 2022, up 32.57% from previous year.
  • 3D Medicines Inc. reported an annual EBITDA of -1.44 Billion CNY in 2021, down -131.66% from previous year.
  • 3D Medicines Inc. reported a quarterly EBITDA of -63.55 Million CNY for 2024 Q2, down 0.0% from previous quarter.
  • 3D Medicines Inc. reported a quarterly EBITDA of -102.54 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of 3D Medicines Inc. (2023 - 2020)

Historical Annual EBITDA of 3D Medicines Inc. (2023 - 2020)

Year EBITDA EBITDA Growth
2023 -529.23 Million CNY 53.41%
2022 -1.02 Billion CNY 32.57%
2021 -1.44 Billion CNY -131.66%
2020 -303.34 Million CNY 0.0%

Peer EBITDA Comparison of 3D Medicines Inc.

Name EBITDA EBITDA Difference
Uni-Bio Science Group Limited 91.23 Million HKD 680.083%
CK Life Sciences Int'l., (Holdings) Inc. 486.79 Million HKD 208.718%